In vitro antifungal activity of amphotericin B and eleven comparators against Aspergillus terreus species complex

H Badali1, A Vaezi1, C Lass-Flörl 2, E Dannaoui 3, JF Meis 4, S Khodavaisy5

Author address: 

1Department of Medical Mycology and Parasitology/Invasive Fungi Research Cen, Mazandaran University of Medical Sciences, Sari, Iran 2Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Austria 3Université Paris-Descartes, Faculté de Médecine, APHP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Paris, France 4Center of Expertise in Mycology, Radboudumc/CWZ, Nijmegen, Netherlands 5Division of Molecular Biology, Department of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Science, Tehran, Iran


Purpose: Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to amphotericin B, and higher mortality compared to infections caused by other Aspergillus species. The aim of the present study was to determine the in vitro antifungal activity of amphotericin B and eleven comparators against clinical (n = 36) and environmental (n = 45) A. terreus isolates

Methods: In vitro antifungal susceptibility was performed using the CLSI M38-A2 procedure.

Results: Amphotericin B exhibited the highest MICs (MIC range, 0.125 to 4 µg/ml; MIC90, 2 µg/ml), followed by terbinafine (MIC range, 0.002 to 1 µg/ml; MIC90, 1 µg/ml). Only one isolate (1/81) showed amphotericin B MIC above the epidemiologic cutoff value (ECV; 4 μg/ml). None of the isolates had a MIC of ≥ ECV for voriconazole, itraconazole and posaconazole.

Conclusion: The reasons for the difference in amphotericin B susceptibility patterns between studies remain unknown. The genetic and species diversity, clinical, environmental and ecological factors in Terrei section on various amphotericin B susceptibility profiles in different countries should be considered more as the main reasons associated with these differences.


Full conference title: 

The 8th Advances Against Aspergillus, Lisbon Conference Center, Lisbon, Portugal
    • AAA 8th (2018)